source
- Endeavor BioMedicines reports positive phase 2b results for Hedgehog inhibitor taladegib in IPFEndeavor BioMedicines announced that its Hedgehog pathway inhibitor, taladegib, produced encouraging results in a phase 2b study of patients with idiopathic pulmonary fibrosis (IPF). The trial, nam…
- Roche partners with Chinese biotech Defand Therapeutics to co-develop new medicinesRoche announced a partnership with Chinese biotech startup Defand Therapeutics aimed at joint discovery of new drug candidates. Unlike the typical licensing deals where companies obtain rights to…